Table 8). This PCAT18-associated expression signature (PES) was then uploaded into Oncomine to identify clinically meaningful associations and to perform pathway analysis (thresholds: p<E−4 odds ratio>2). PES was consistently up-regulated in PCa vs. normal tissue and PCa vs. other neoplasms in several cancer studies, comprising more than 4000 human samples (Table 1). More interestingly, PES was significantly activated in metastatic vs. primary PCa samples. Pathway analysis revealed that PES is strongly associated with androgen receptor (AR) activation (Fig. 3A). Here, PCAT18 is linked to posterior cortical atrophy.